CME Funding Not Reportable Under Sunshine Law, But Bias Debate Continues
ACCME report finds “no evidence to support or refute” belief that commercial support creates commercial bias in CME activities.
You may also be interested in...
CMS releases data on $3.5 billion worth of payments made by drug and device companies to physicians and teaching hospitals in the last five months of 2013; an additional 199,000 payment records were not disclosed.
Accreditation Council for Continuing Medical Education reports that commercial support for CME activities declined in 2011 but the number of activities increased 3.8%; more than 20 million participated in CME programs.
After agency tightened bioequivalence testing recommendations for tacrolimus products post approval, studies found Accord’s generic version of Prograf may deliver higher concentrations, leading agency to downgrade its therapeutic equivalence rating. No problems were found with five other tacrolimus ANDAs.